CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 37 enrolled
Drug / intervention
Standard Care +1 morebehavioral
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04897607
NCT04897607N/ACompleted
CompareCT.gov

A Pilot Pragmatic RCT of a Hospital-based Precision Pharmacotherapy Smoking Cessation Program

Christiana Care Health Services·interventional·Posted May 21, 2021·Updated Mar 31, 2023

In Brief

A clinical study evaluating Standard Care and Precision pharmacotherapy for Smoking Cessation. Completed, enrolled 37 participants across 1 site.

Detailed Summary

The purpose of this study is to determine the benefits of a personalized treatment approach, compared to a non-personalized treatment approach, for smoking cessation. In other words, this study will help us know if recommending a specific medication to individual smokers will make it easier to quit smoking than simply offering an option of medications. The specific recommendation for a medication will be based on a test that measures how quickly a smoker breaks down, or metabolizes, nicotine.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSmoking Cessation
CountriesUnited States
CollaboratorsUniversity of Delaware, National Institute of General Medical Sciences (NIGMS)

Timeline

N/ACompletedFinished
20222023202420252026
First PostedMay 21, 2021
Enrollment StartFeb 23, 2022
Primary CompletionDec 31, 2022
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 5.1 years ago

Interventions

Standard Carebehavioral

Participants will be advised to quit smoking and offered a choice of nicotine replacement patches or varenicline. Participants are free to decline medication.

Precision pharmacotherapybehavioral

Participants will be advised to quit smoking and provided a medication recommendation on the basis of their nicotine metabolite ratio (NMR) test (i.e., nicotine replacement patches for slower metabolizers, varenicline for faster metabolizers). Participants are free to choose either medication or decline any medication.